A multicenter retrospective observational study to evaluate the efficacy and safety of durvalumab following concurrent chemoradiotherapy for stage III non-small cell lung cancer harboring EGFR mutation (NEJ063 study)
Not Applicable
- Conditions
- on-small cell lung cancer
- Registration Number
- JPRN-UMIN000051670
- Lead Sponsor
- Tohoku University Hospital
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Pending
- Sex
- All
- Target Recruitment
- 300
Inclusion Criteria
Not provided
Exclusion Criteria
(1) Cases treated with sequential combination of chemotherapy and radiotherapy. (2)Cases that the physician judged to be inappropriate for reasons such as inability to collect the information necessary to fill out the CRF.
Study & Design
- Study Type
- Observational
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Progression free survival from the end of chemoradiotherapy in the chemoradiotherapy plus durvalumab and chemoradiotherapy alone groups
- Secondary Outcome Measures
Name Time Method 1) Overall survival from the time of completion of chemoradiotherapy in the chemoradiotherapy plus durvalumab and chemoradiotherapy alone groups 2) Progression-free survival and overall survival by year from the end of chemoradiation therapy in the chemoradiation therapy plus durvalumab and chemoradiation therapy alone groups 3) Treatment safety in patients receiving chemoradiation followed by durvalumab 4) Patient characteristics of the long-term progression-free survival cohort in the durvalumab arm 5) Safety of EGFR-TKI as post-therapy in patients treated with durvalumab